Success Metrics

Clinical Success Rate
53.8%

Based on 7 completed trials

Completion Rate
54%(7/13)
Active Trials
0(0%)
Results Posted
100%(7 trials)
Terminated
6(46%)

Phase Distribution

Ph phase_1
4
31%
Ph phase_2
4
31%
Ph phase_3
5
38%

Phase Distribution

4

Early Stage

4

Mid Stage

5

Late Stage

Phase Distribution13 total trials
Phase 1Safety & dosage
4(30.8%)
Phase 2Efficacy & side effects
4(30.8%)
Phase 3Large-scale testing
5(38.5%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

53.8%

7 of 13 finished

Non-Completion Rate

46.2%

6 ended early

Currently Active

0

trials recruiting

Total Trials

13

all time

Status Distribution
Completed(7)
Terminated(6)

Detailed Status

Completed7
Terminated6

Development Timeline

Analytics

Development Status

Total Trials
13
Active
0
Success Rate
53.8%
Most Advanced
Phase 3

Trials by Phase

Phase 14 (30.8%)
Phase 24 (30.8%)
Phase 35 (38.5%)

Trials by Status

terminated646%
completed754%

Recent Activity

0 active trials
Showing 5 of 13
completedphase_1

Drug Interaction Study Between AVP-923 and Itraconazole and Between AVP-786 and Itraconazole in Healthy Adult Subejcts

NCT02402595
completedphase_1

A Phase-1 Study to Assess the Pharmacokinetics, Safety and Tolerability of AVP-786 in Healthy Volunteers

NCT02174835
completedphase_1

A Phase 1 Study Comparing AVP-786 With AVP-923

NCT02336347
terminatedphase_3

Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

NCT02446132
terminatedphase_3

Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

NCT04464564
View all 13 trials

Clinical Trials (13)

Showing 13 of 13 trials
NCT02402595Phase 1

Drug Interaction Study Between AVP-923 and Itraconazole and Between AVP-786 and Itraconazole in Healthy Adult Subejcts

Completed
NCT02174835Phase 1

A Phase-1 Study to Assess the Pharmacokinetics, Safety and Tolerability of AVP-786 in Healthy Volunteers

Completed
NCT02336347Phase 1

A Phase 1 Study Comparing AVP-786 With AVP-923

Completed
NCT02446132Phase 3

Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

Terminated
NCT04464564Phase 3

Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

Terminated
NCT04408755Phase 3

Assessment of the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

Terminated
NCT03393520Phase 3

Assessment of the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

Completed
NCT03896945Phase 2

Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Negative Symptoms of Schizophrenia

Terminated
NCT02442765Phase 3

Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

Completed
NCT03420222Phase 2

Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Intermittent Explosive Disorder

Terminated
NCT02174822Phase 1

A Phase 1, Drug Interaction Study Between AVP-786 and Paroxetine and Between AVP-786 and Duloxetine in Healthy Subjects

Completed
NCT02534038Phase 2

Safety, Tolerability and Efficacy of AVP-786 for the Treatment of Disinhibition

Terminated
NCT02477670Phase 2

Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Residual Schizophrenia

Completed

All 13 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
13